Cover Image
市場調查報告書

韋格納肉芽腫的開發中產品分析

Wegener's Granulomatosis - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 302489
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
韋格納肉芽腫的開發中產品分析 Wegener's Granulomatosis - Pipeline Review, H1 2015
出版日期: 2015年05月13日 內容資訊: 英文 45 Pages
簡介

韋格納肉芽腫是血管發炎引起的一種絕症,特徵為血管發炎造成血流到各個人體組織受到阻礙。主要症狀有持績性的鼻水鼻血、耳朵感染、咳嗽、胸痛、皮膚潰爛、發燒等。此外,年齡等也是主要致病要素。主要治療法有免疫疾病抑制治療和皮質類固醇劑等。

本報告提供全球各國治療韋格納肉芽腫用的開發中產品開發情形分析,提供產品開發·上市的最新趨勢,及各階段臨床實驗產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

韋格納肉芽腫概要

治療藥的開發

  • 韋格納肉芽腫用開發中產品:概要
  • 韋格納肉芽腫用開發中產品:比較分析

各企業開發中的韋格納肉芽腫治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

韋格納肉芽腫治療藥:開發中的產品一覽(各企業)

韋格納肉芽腫治療藥的開發作的企業

  • Amgen Inc.
  • Celltrion, Inc.
  • 日本化藥
  • Panacea Biotec Limited
  • Anthera Pharmaceuticals, Inc.
  • Biosidus S.A.
  • Aprogen, Inc.
  • Curaxys, S.L.
  • Epirus Biopharmaceuticals, Inc.

韋格納肉芽腫:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子類別

藥物簡介

  • gusperimus trihydrochloride
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • blisibimod
  • Rituximab的生技仿製藥(其之1∼其之8)

韋格納肉芽腫治療藥:開發中產品的最新趨勢

韋格納肉芽腫治療藥:開發暫停的產品

韋格納肉芽腫治療藥:開發中止的產品

韋格納肉芽腫相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全5件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6760IDB

Summary

Global Markets Direct's, 'Wegener's Granulomatosis - Pipeline Review, H1 2015', provides an overview of the Wegener's Granulomatosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wegener's Granulomatosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wegener's Granulomatosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wegener's Granulomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wegener's Granulomatosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wegener's Granulomatosis Overview
  • Therapeutics Development
    • Pipeline Products for Wegener's Granulomatosis - Overview
    • Pipeline Products for Wegener's Granulomatosis - Comparative Analysis
  • Wegener's Granulomatosis - Therapeutics under Development by Companies
  • Wegener's Granulomatosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Wegener's Granulomatosis - Products under Development by Companies
  • Wegener's Granulomatosis - Companies Involved in Therapeutics Development
    • Aprogen, Inc.
    • ChemoCentryx, Inc.
    • Epirus Biopharmaceuticals, Inc.
    • Hospira, Inc.
    • Panacea Biotec Limited
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
  • Wegener's Granulomatosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Wegener's Granulomatosis - Recent Pipeline Updates
  • Wegener's Granulomatosis - Dormant Projects
  • Wegener's Granulomatosis - Discontinued Products
  • Wegener's Granulomatosis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wegener's Granulomatosis, H1 2015
  • Number of Products under Development for Wegener's Granulomatosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Wegener's Granulomatosis - Pipeline by Aprogen, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by ChemoCentryx, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Hospira, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Panacea Biotec Limited, H1 2015
  • Wegener's Granulomatosis - Pipeline by Sandoz International GmbH, H1 2015
  • Wegener's Granulomatosis - Pipeline by Therapeutic Proteins International, LLC, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Wegener's Granulomatosis Therapeutics - Recent Pipeline Updates, H1 2015
  • Wegener's Granulomatosis - Dormant Projects, H1 2015
  • Wegener's Granulomatosis - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Wegener's Granulomatosis, H1 2015
  • Number of Products under Development for Wegener's Granulomatosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top